Lenacapavir: A Major HIV Breakthrough That Must Reach Everyone

A new chapter in HIV treatment and prevention is emerging, with lenacapavir offering hope to people who face some of the toughest challenges in managing or preventing HIV. The long-acting medicine has attracted international attention because it can be administered by injection only twice a year for HIV prevention, potentially removing one of the biggest practical barriers associated with daily medication.

In England, the NHS is preparing to make lenacapavir available to hundreds of people living with multidrug-resistant HIV who have limited treatment options. The development has been welcomed by HIV campaigners and health organisations because the medicine could provide an important additional option for people whose virus has become resistant to several existing treatments.

However, the growing availability of lenacapavir in wealthier countries has also raised a wider global health question: who will be able to benefit from this medical breakthrough?

What is lenacapavir?

Lenacapavir is a long-acting HIV medicine developed by Gilead Sciences. Unlike many traditional HIV medicines that require regular daily dosing, the drug has been developed in formulations that can significantly reduce the frequency of administration.

This is particularly important for HIV prevention. Taking medication every day can be difficult for some people because of stigma, discrimination, concerns about disclosure, financial pressures, travel, limited healthcare access and other social circumstances.

A twice-yearly injection could therefore offer an alternative that is easier for some people to incorporate into their lives.

The potential significance extends beyond individual convenience. HIV continues to affect communities around the world, and barriers to prevention and treatment remain particularly serious in countries with limited healthcare resources.

Why access and affordability matter

The development of an effective medicine does not automatically mean that everyone who needs it can obtain it.

According to the source material, lenacapavir can cost tens of thousands of US dollars per person each year in wealthy markets. At the same time, generic versions are expected to become available at substantially lower prices in eligible low-income countries.

This creates a major disparity in access.

Some countries that have participated in clinical research and contributed to the development of HIV innovations can still face significant challenges in obtaining affordable prevention medicines. Brazil, Mexico and Peru are among the countries identified in the source material as having hosted clinical trials while facing different pricing and access circumstances.

For advocates, this raises an important question about how medical innovation should be distributed.

If a medicine has the potential to transform HIV prevention, its impact will be limited if the people and communities with substantial unmet need cannot afford or obtain it.

The promise of twice-yearly HIV prevention

One of the most closely watched aspects of lenacapavir is its potential role in HIV prevention.

Daily oral prevention, known as PrEP, has played an important role in reducing the risk of HIV infection. Yet daily medication does not work equally well for everyone. Some people may struggle to remember doses, while others may avoid medication because they fear stigma or cannot reliably access healthcare services.

Long-acting prevention could address some of these barriers.

The twice-yearly approach could be particularly relevant for people who find daily tablets difficult to maintain. It may also provide an additional choice within HIV prevention services, allowing healthcare professionals and patients to consider different approaches according to individual circumstances.

However, prevention medicines only have a population-level effect when they are accessible at sufficient scale.

That means affordability, manufacturing capacity, healthcare infrastructure and reliable supply chains are all important parts of the discussion.

Calls for a lower global price

Médecins Sans Frontières has launched a campaign calling for broader access to lenacapavir under the message "Lenacapavir: Two Shots. $40. Everywhere."

The campaign focuses on three main priorities.

First, it calls for the price of lenacapavir to be reduced to below US$40 per person per year across low- and middle-income countries.

Second, it calls for global production to be expanded so that supply can meet demand.

Third, it asks that organisations working directly with affected communities, including humanitarian organisations, be able to purchase the medicine directly.

These proposals reflect a broader debate about how pharmaceutical innovation can be made available in countries where healthcare budgets are significantly smaller than those of high-income nations.

The role of the UK

The NHS decision means people in England could benefit from an important advance in HIV medicine. But the wider question is how the UK responds to the global implications of that innovation.

The UK has historically played a significant role in international HIV programmes and global health initiatives. Organisations such as Unitaid and the Global Fund have supported efforts to expand access to HIV prevention, diagnosis and treatment.

Continued international cooperation could be important as countries prepare for wider deployment of long-acting HIV prevention.

The debate also comes at a time when international development budgets are under pressure. Reduced funding for global health programmes could make it more difficult for organisations to introduce new medicines and maintain existing HIV services.

For campaigners, investment in global health is therefore closely connected to the goal of ending AIDS as a public health threat.

Reaching the 2030 goal

The international community has set ambitious targets for ending AIDS as a public health threat by 2030. Achieving that goal will require more than developing new medicines.

Prevention, testing, treatment, education, healthcare access and human rights all remain essential components of the global HIV response.

New technologies such as long-acting prevention could accelerate progress, but only if they reach people who need them.

There is also a wider lesson for future medical breakthroughs. Scientific progress can save lives, but unequal access can prevent those advances from delivering their full potential.

Lenacapavir demonstrates both sides of that equation. Its development represents significant progress in HIV medicine, while the debate over pricing and availability highlights the continuing challenge of making innovation equitable.

What happens next?

The coming years could be important for determining how widely lenacapavir becomes available.

Governments, pharmaceutical companies, international health organisations, donors and community groups all have roles to play. Expanding manufacturing, establishing sustainable pricing arrangements and strengthening healthcare systems will be important if long-acting HIV prevention is to reach large populations.

For people living with HIV who have limited treatment options, access to lenacapavir could represent a valuable new opportunity. For people seeking to prevent HIV, twice-yearly administration could provide an alternative to daily medication.

The challenge is ensuring that geography and income do not become the deciding factors in who can benefit from the technology.

A medical breakthrough becomes truly transformative when it can be delivered at the scale required by the communities it is intended to serve. Lenacapavir has the potential to become an important part of the global HIV response, but achieving that potential will depend not only on scientific innovation, but also on affordability, supply and equitable access.

Source

The Independent on 21 August 2026.

Disclaimer

This article is for general informational purposes only and is not medical advice. HIV prevention and treatment decisions should be discussed with a qualified healthcare professional. Availability, eligibility, pricing and prescribing arrangements for lenacapavir can vary by country and may change over time. Readers should consult official health authorities and healthcare providers for the most current information.